Chen Chengqian, Zhong Wentao, Zheng Hao, Zhao Wei, Wang Yushi, Shen Botao
Department of Cardiology Center, The First Hospital of Jilin University, Changchun, China.
Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, China.
Front Cardiovasc Med. 2025 Apr 28;12:1518036. doi: 10.3389/fcvm.2025.1518036. eCollection 2025.
Heart failure (HF) represents the terminal stage of cardiovascular disease and remains a leading cause of mortality. Epidemiological studies indicate a high prevalence and mortality rate of HF globally. Current treatment options primarily include pharmacological and non-pharmacological approaches. With the development of mesenchymal stem cell (MSC) transplantation technology, increasing research has shown that stem cell therapy and exosomes derived from these cells hold promise for repairing damaged myocardium and improving cardiac function, becoming a hot topic in clinical treatment for HF. However, this approach also presents certain limitations. This review summarizes the mechanisms of HF, current treatment strategies, and the latest progress in the application of MSCs and their exosomes in HF therapy.
心力衰竭(HF)是心血管疾病的终末期阶段,仍然是主要的死亡原因。流行病学研究表明,全球HF的患病率和死亡率都很高。目前的治疗选择主要包括药物治疗和非药物治疗方法。随着间充质干细胞(MSC)移植技术的发展,越来越多的研究表明,干细胞疗法以及源自这些细胞的外泌体有望修复受损心肌并改善心脏功能,成为HF临床治疗中的一个热门话题。然而,这种方法也存在一定的局限性。本综述总结了HF的发病机制、当前的治疗策略以及MSCs及其外泌体在HF治疗中的应用的最新进展。
Front Cardiovasc Med. 2025-4-28
Curr Stem Cell Res Ther. 2021
Stem Cell Res Ther. 2025-1-23
J Cardiovasc Transl Res. 2024-6
Curr Cardiol Rep. 2022-4
Am J Physiol Heart Circ Physiol. 2024-9-1
Stem Cell Rev Rep. 2024-8
JACC Heart Fail. 2024-5
Medicina (Kaunas). 2024-1-27